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Abstract. We present in this paper a new mathematical model designed to optimize and to
rationalize the association between cytotoxic and antiangiogenic drugs in the treatment of a
primary tumor. This model takes into account the non-linear interlinkings between both drugs.
In particular, this original model integrates the influence of the vasculature state on the delivery
of the drugs to the tumor. In the future, this model could be used in clinical oncology to optimize
antiangiogenic-based combinational regimen so as to ensure a maximum efficacy.
Résumé. Nous proposons ici un nouveau modèle mathématique dédié à l’optimisation
thérapeutique des combinaisons antiangiogéniques/cytotoxiques en cancérologie. Ce modèle
permet de rendre compte des interactions non-linéaires entre les deux traitements et notam-
ment de l’influence de l’état de la vasculature sur l’accès à la tumeur des molécules admin-
istrées. A terme, ce modèle pourra être utilisé en oncologie clinique pour piloter les protocoles
chimiothérapeutiques reposant sur la combinaison d’un antiangiogénique et de médicaments
cytotoxiques, afin d’en améliorer l’efficacité antitumorale.
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Version française abrégée
La découverte du phénomène d’angiogénèse tumorale par J. Folkman [8] en 1971
a permis la mise en place de traitements antiangiogéniques des cancers et préfigure
l’avènement des thérapies dites ciblées, au début des années 2000. Ces traitements
sont généralement administrés en parallèle avec un ou plusieurs agents cytotoxiques
classiques. Les agents cytotoxiques inhibent la réplication tumorale en induisant une
mort cellulaire, le plus souvent de nature apoptotique. Les antiangiogéniques, en in-
terférant avec les voies de signalisation impactant sur la formation de néo-vaisseaux,
diminuent l’apport de nutriments et d’oxygène à la tumeur et limitent ainsi sa crois-
2sance. En combinant les deux, on peut espérer avoir un effet synergique. Toutefois,
en pratique clinique, les associations thérapies ciblées/cytotoxiques reposent, dans
leurs modalités d’administration, essentiellement sur des considérations pratiques et
logistiques liées au protocole chimiothérapeutique choisi et à la présence effective du
patient dans le service. Or, en affectant la vasculature tumorale, il n’est pas impossi-
ble qu’un traitement antiangiogénique freine également le bon accès au site d’action
des cytotoxiques co-administrés. Dans ce contexte, on peut emmettre l’hypothèse
qu’il existe une modalité optimale d’association entre ces deux types de traitements.
Nous proposons ici un modèle mathématique qui permet de rendre compte de l’état
du réseau vasculaire de la tumeur (influencé par le traitement antiangiogénique) sur
l’apport et donc l’efficacité des médicaments. Il est centré sur les équations suivantes :
dn
dt (t) = λn(t) log
(
s(t)
n(t)
)
− kq(t)s(t)C(t)n(t)
ds
dt (t) = χu(t)− τs(t)
du
dt (t) = −χu(t) + γn(t)− δn(t)
2
3u(t)− ηq(t)s(t)A(t)u(t)
où n représente le nombre de cellules tumorales, s la quantité de vaisseaux stables, u
la quantité de vaisseaux instables, q la qualité de la vasculature, C la concentration ef-
fective en agent cytotoxique etA la concentration effective en agent antiangiogénique.
Ces équations sont dérivées des modèles de Gompertz [9] et de Hahnfeldt et al. [10].
Les concentrations effectives sont calculées à l’aide de modèles pharmacocinétiques
et pharmacodynamiques [2].
En résolvant numériquement ce modèle dans le cas d’une thérapie couplée etopo-
side oral et bevacizumab, on constate effectivement qu’à dose égale, le délai en-
tre l’administration des différents agents influence fortement l’impact du traitement
sur la croissance tumorale (fig. 1). Il semble plus intéressant d’administrer l’agent
antiangiogénique en premier afin qu’il améliore la qualité de la vasculature avant
d’administrer l’agent cytotoxique. En cela, on retrouve les conclusions de Jain [12].
On peut alors chercher numériquement le délai optimal pour minimiser la taille min-
imale de la tumeur (fig. 2). On obtient une durée de 6 à 7 jours correspondant à
l’intervalle optimal d’utilisation séquentielle des deux molécules. Certains paramètres
du modèle ayant été fixés arbitrairement, les résultats numr´iques présentés ici ne peu-
vent être directement transférés en clinique mais il apparaît clairement que le calcul de
la posologie optimale (doses et temps d’administration) pour ces traitements couplés
pourrait grandement impacter l’efficacité de ces thérapies.
1. Introduction
A cancer is an abnormal cell proliferation within a tissue. This proliferation is
generally due to genetic mutations in a single normal cell leading to dysregulation of
the cell division and inability to undergo programmed cell-death or apoptosis. The
resulting dividing cells can form a tumor localised to the organ (primary tumor) or
subsequently disseminate throughout the body (secondary tumor or metastases). Here
we will consider the antiproliferative effect of a combined therapy on the growth of a
3primary tumor only.
Conventional treatments consist in blocking cell division and eventually killing cancer
cells with cytotoxic agents. Such agents act on all rapidly dividing cells, i.e. most tu-
mor cells as well as bone marrow, intestinal or folicles. Thus, they have numerous and
possibly life-threatening side effects which frequently require a decrease in dosing or
treatment discontinuation until the patient recovers.
Another therapeutic possibility takes advantage of oxygen and nutrient requirements
for proper tumor growth. Oxygen and nutrients being supplied by blood, tumors de-
velop new blood vessels to ensure their growth. This process, termed tumor angio-
genesis, was discovered in the 1970’s by Judah Folkman [8]. Without angiogenesis,
admittedly the size of most primary tumors would not exceed 2 − 3 mm. To pro-
mote new vessels formation, cancer cells secrete specific growth factors like VEGF
(Vascular Endothelial Growth Factor). These factors bind to receptors on vascular
endothelial cells and stimulate their proliferation and migration to the tumor. Several
other exocrine factors like PDGF, SDF1, PIGF or FGF2 are now recognized as regu-
lating the neo-angiogenic process in the tumor environment. This discovery led to the
new era of antiangiogenic therapies, whose purpose is to inhibit new vessels forma-
tion and thus tumor growth ultimately. To date, the humanized monoclonal antibody
bevacizumab is the only marketed drug that acts directly as an antiangiogenic agent
by targeting circulating VEGF, thus preventing it to reach its receptor and to promote
neoangiogenesis. Bevacizumab has been approved for treating breast and colorectal
cancers in combination with various cytotoxics, and is currently under clinical inves-
tigations in a variety of solid tumors like lung cancer. In this paper, bevacizumab will
be used as the paradigm of antiangiogenic drugs.
Our aim is to develop a mathematical model describing a combinational therapy using
a cytotoxic agent (we have chosen etoposide) and bevacizumab in a localized tumor.
The originality of our model is to take into account the interactions between the two
drugs, in particular the influence of the quantity and quality of the vasculature on the
delivery of the drugs to the tumor.
2. Model
Our model of combination therapy is based on already well known models. We
have chosen to start from the classical model of tumor growth of Gompertz [9] where
the number of cancer cells n follows the law
dn
dt
(t) = λn(t) ln
(
θ
n(t)
)
(1)
with θ a constant which we will call carrying capacity. This constant represents the
maximal size the tumor could reach. This original model does not take into account
the process of angiogenesis. That is why Hahnfeldt et al. [10] have proposed a mod-
ification of the Gompertz model which considers the carrying capacity as a variable
4linked to the size of the vasculature at the given time and no longer as a constant.
Equation (1) becomes
dn
dt
(t) = λn(t) ln
(
θ(t)
n(t)
)
. (2)
In Hahnfeldt’s model, the dynamics of the carrying capacity is the result of a balance
between a term of stimulation of the vasculature by the tumor cells and a term of
inhibition. Indeed, without inhibition, the vasculature would become anarchical and
inefficient for tumor growth. Thus
dθ
dt
(t) = bn(t)− dn(t) 23 θ(t). (3)
It remains to add the effects of combination of the cytotoxic (CT) and the antian-
giogenic (AA) agents. A pharmacokinetic and pharmacodynamic approach as the one
developed in [2] is necessary to link the doses of drugs administred to their effective
concentrations. We denote C(t) the effective concentration of CT and A(t) the effective
concentration of AA.
Since the cytotoxic agent decreases tumor growth rate, the tumor growth equation
(2) becomes
dn(t)
dt
= λn(t) log
(
θ(t))
n(t)
)
− kC(t)n(t). (4)
For its part, the antiangiogenic drug adds an inhibition term in the evolution of the
carrying capacity and equation (3) becomes
dθ
dt
(t) = bn(t)− dn(t) 23 θ(t)− eA(t)θ(t). (5)
However, the model (4)-(5) does not allow to assess the interactions between the two
treatments and in particular the influence of the vasculature state on the delivery of CT
and AA to the tumor. To take into account such interactions, we propose a modifica-
tion of this model that consists in separating the vasculature into stable (mature) and
unstable (immature) vessels.
Variables. We denote in the sequel n the number of cancer cells, s and u variables
related respectively to the density of stable and unstable vessels. Let C and A be the
effective concentrations of cytotoxic agent and of antiangiogenic agent.
Biological hypotheses. Our model is build from the Hahnfeldt et al. model
(2), (3) with the following additional assumptions on the vasculature. Only stable
vessels supply nutrients and oxygen, s will thus substitute for the carrying capacity
θ of Hahnfeldt’s model. Only stable vessels supply pharmacological agents. Only
unstable vessels are subjected to stimulatory and inhibitory signals coming from the
tumor. Unstable vessels maturate with a constant rate denoted by χ, stable vessels are
subject to natural death (apoptosis) with a rate τ .
For the dynamics of the therapy, we assume moreover that the effects of the agents
are proportional to their effective concentration but with a constant depending on the
5density of the vasculature and on the quality of this vasculature. The antiangiogenic
agent bevacizumab acts as a vessel disruptive agent only on immature vessels. The
quality of the vasculature for distributing the pharmacological agents depends on the
proportion of stable vessel in the vasculature. Let us introduce the function q(t) =
s(t)
s(t)+u(t) , to describe this quality of the vasculature
Equations. Starting from these biological hypotheses, the equations of our model
are 
dn
dt (t) = λn(t) log
(
s(t)
n(t)
)
− kq(t)s(t)C(t)n(t),
ds
dt (t) = χu(t)− τs(t),
du
dt (t) = −χu(t) + γn(t)− δn(t)
2
3u(t)− ηq(t)s(t)A(t)u(t).
(6)
Parameter values. The parameter values used in the illustrations below are fixed
to reproduce the growth of a human tumor in absence of treatment like in [11]. We set
λ = 4.2× 10−3, χ = 7.56× 10−3, τ = 7.5× 10−3, γ = 1 and δ = 5.73× 10−8.
The parameters k and η as well as the effective concentrations C(t) and A(t)
depend on the chosen therapy. In the following, we opted for oral etoposide and beva-
cizumab. The cytotoxic agent etoposide follows a one-compartment pharmacokinetic
model as described by Jong et al. [13], the effective concentration C(t) being the
concentration in this compartment above a threshold. The antiangiogenic agent fol-
lows a two-compartment pharmacokinetic model as described by Bruno et al. [6],
the effective concentration A(t) being the concentration in the second compartment
above a threshold. The linear ordinary differential equations obtained with this ap-
proach will not be described here (see [2] or [5] for more details). We arbitrarily fixed
k = 1.37× 10−9 and η = 6.85× 10−11 in order to obtain realistic drug effects.
3. Illustrations
We investigate in this section the performance of this new model for studying the
interactions between etoposide and bevacizumab, depending on the way the drugs are
given. To support our hypothesis, we have chosen to simulate the impact of varia-
tions in time interval between the administrations of bevacizumab and oral etoposide,
a regimen that has been tested recently to treat glioblastomas. In section 3.1, we will
illustrate the effect of two distinct protocols on the tumor and its vasculature. In sec-
tion 3.2, we will further show how our model allows to optimize the administration of
the drugs in a given protocol.
3.1. Evolution of tumor size and vessels during a cycle of chemotherapy
Current combinational therapies are administered as successive courses, whom
frequency and duration are mostly limited by a Maximal Tolerated Dose (MTD), when
6it is not by logistic considerations such as availability of the patient in the medical
unit. Although dosage and periodicity of the courses (ie, usually from one to three
weeks) are supposed to remain the same for a given protocol, frequent changes occur
due to appearance of treatment-related toxicities in patients that require delay in the
administration of the forthcoming courses, or reduction in dosage. In addition, a same
protocol can be administered following a wide range of modalities, thus leading to
numerous variations. Overall, it is widely acknowledged now that most anticancer
regimen are administered on a rather empirical basis [7, 14].
(a) Number of tumor cells (b) Stable vessels
(c) Unstable vessels (d) Quality of vasculature
Figure 1. Evolution of tumor size, quantity of stable and unstable vessels, and qual-
ity of vasculature in six different protocols. Without treatment: no drug is admin-
istered. CT alone: oral etoposide is administered from day 1 to day 5 but no anti-
angiogenic agent is given. AA alone: bevacizumab is administered on day 1 but no
cytotoxic agent is given. AA then CT: bevacizumab is administered on day 1 fol-
lowed by the administration of oral etoposide from day 8 to day 13. CT then AA:
oral etoposide is administered from day 1 to day 5 followed by the administration of
bevacizumab on day 8. AA and CT: oral etoposide is administered from day 1 to day
5 and bevacizumab is given on day 1.
7With our model, we have simulated the evolution in size of a given tumor over a
course of 21-days with different drugs. Our main focus was the impact of the wait
between etoposide and bevacizumab administrations on treatment efficacy, rather than
the impact of the drug dosage. Thus every time the AA agent is administred, 525 mg
of bevacizumab is given as a short infusion. Concerning the CT agent, the patient
takes orally 212 mg a day during five consecutive days.
Figure 1 presents the results of our model when no treatment is given, when a
single agent (AA or CT) is given, when both agents are given simultaneously and
when both agents are given with a delay of one week between the administrations
(AA then CT and CT then AA). The posology has obviously a strong influence on the
final size of the tumor and even when both drugs are given, the issue of the treatment
depends strongly on the order the drugs are given. With this model, the treatment that
obtains the best results consists in giving bevacizumab first and etoposide one week
later.
These results are consistent with the observations of Jain in [12]. In this paper, Jain
assumes that in a first concentration range, bevacizumab could lead to a normalisation
of the vasculature, hence to a better delivery of etoposide. In the same paper, he
claims also that, in a higher concentration range, bevacizumab could disrupt most
of the vasculature and thus impair the delivery of etoposide, we have not tested this
fact yet. Figures 1(b) and 1(d) shows that, in the concentration range we have used,
bevacizumab significantly increases the quality of the vasculature without disrupting
all stable vessels which deliver etoposide.
The final purpose of this model is to provide an insight on how both drugs can be
best combined to ensure a maximum efficacy. Once the model is set up, in silico
simulations can help to predict the various effects on tumor growth reduction, so as to
chose the best regimen. In this feasibility study, our data strongly suggest that the best
sequence is antiangiogenic followed by the cytotoxic agent.
3.2. Optimization of the time interval between the administrations of bevacizumab
and of etoposide
We are now interested in optimizing the effect of the combination therapy by ad-
justing the delay between the administrations of both agents. The agents are given
with the same dosage as in the previous section. As suggested by the preceding re-
sults, bevacizumab is given first to normalize the vasculature. Figure 2(a) shows the
evolution of the tumor during 3 cycles of combination therapy for various delay in the
administration of both agents and figure 2(b) shows the minimum size of the tumor
over the 3 cycles depending on the delay between the administration of both agents.
On this figure, we observe that the best delay is about one week. This optimal delay
may depend on the parameter values (specially on k and η which were fixed arbitrar-
ily) but it seems that there always exists a minimum.
8(a) Evolution of the tumor size (b) Minimum tumor size depending on the
delay
Figure 2. Optimization of the combination therapy. Bevacizumab is administered on
day 1 and etoposide is administered during 5 days after a delay of 0 to 17 days.
4. Conclusion and perspectives
This work is a novel approach to describe the effects of a combination between
cytotoxic and antiangiogenic agents. Its originality is to take into account the nonlin-
ear interlinkings between the two drugs. Our illustrations clearly show that this new
model is able to describe a part of these interlinkings and that the consequences of
these effects should not be neglected when a protocol of combination therapy is estab-
lished.
For now, the model, beside the description of the effects of the combination on tumor
growth, can be used to optimize and to rationalize the association between antian-
giogenic and cytotoxic drugs. But in this preliminary study, we have used a set of
parameter values which should be adjusted to each individual patient. A sensitivity
study of these parameters will have to be carried out and set against non-clinical data
obtained in mice, so as to adjust the model.
An interesting feature will be to further extend this approach to the treatment of
metastatic cancer as in [1, 3, 4, 5].
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